Anbio Biotechnology (NNNN)
NNNN trades on Nasdaq in Health Care, Biotechnology: In Vitro & In Vivo Diagnostic Substances. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$4.26
-3.40% on the day
Market cap
$613.0M
Small cap
Revenue · 2025
$8.6M
+5.6% on 2024
Net income · 2025
$6.4M
74.1% net margin
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2025.
Profile
| Field | Value |
|---|---|
| Ticker | NNNN on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Country | Germany |
| IPO year | 2025 |
| SEC CIK | 0001982708 |
| SEC industry code | In Vitro & In Vivo Diagnostic Substances |
| Incorporated in | E9 |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $8.6M |
| Net income | $6.4M |
| Operating income | $5.8M |
| Net margin | 74.1% |
| Operating margin | 66.7% |
| Revenue growth | +5.6% |
| Cash | $7.8M |
| Total assets | $30.2M |
| P/E (computed) | 95.7× |
| P/S (computed) | 70.9× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document PROSPECTUS | 424B4 | 2025-02-19 |
| Latest annual report FORM 20-F | 20-F | 2026-04-07 |
| Latest quarterly / interim FORM 6-K | 6-K | 2026-05-19 |
Source: SEC EDGAR submissions feed, 43 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -17.6% |
| 1 month | -26.7% |
| 3 months | -57.9% |
| Year to date | -86.6% |
| 1 year | -85.3% |
| From 52-week high | -90.2% |
Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: In Vitro & In Vivo Diagnostic Substances
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| ACHV | Achieve Life Sciences Inc. Common Shares | $7.00 | -0.85% | $720.3M |
| TKNO | Alpha Teknova Inc. | $8.22 | -5.52% | $441.3M |
| MYGN | Myriad Genetics Inc. | $4.08 | -2.86% | $390.3M |
| QDEL | QuidelOrtho Corporation | $14.10 | +6.42% | $966.9M |
| NTLA | Intellia Therapeutics Inc. | $11.91 | -5.33% | $1.7B |
| CLDX | Celldex Therapeutics Inc. | $28.25 | -4.01% | $2.2B |
| NEOG | Neogen Corporation | $11.73 | -2.25% | $2.6B |
| ICCC | ImmuCell Corporation | $10.79 | +12.40% | $98.0M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier